12
Nov
2020
15:00
GMT
Webinar
Technological Iteration in TAVI: A Live Case Session
-
Views:
550 -
Likes:
0
Overview
Join us for a live discussion and live case performance on:
- Benefits of latest technology iterations in TAVI to increase safety and efficacy
- ACURATE neo2™ in clinical practice: Live case from St. Johannes Hospital, Dortmund
- Design, results, and limitations of TAVI trials involving the ACURATE neo Valve Platform
- How the heart team should individualize the treatment of TAVI patients
Faculty:
Helge Möllmann
Lars Søndergaard
Pablo Lamelas
Won Keun-Kim
This webinar is supported by
Agenda
Faculty Biographies
Helge Möllmann
Prof Helge Möllmann is a distinguished cardiologist and the Director of the Clinic for Internal Medicine (Cardiology) at St Johannes Hospital in Dortmund, Germany. With a prolific career in cardiovascular medicine, he has authored over 520 publications, contributing significantly to the advancement of cardiology research and clinical practice.
Prof Helge Möllmann is an esteemed member of several prominent cardiology organisations, including the German Society for Cardiology (DGK) and the Interventional Cardiology Working Group of the DGK. Prof Helge Möllmann's expertise and leadership are further recognised through his roles as a Nucleus member of the European Society of Cardiology (ESC), as well as his involvement in the German Mitral Valve Steering Committee and the German Aortic Valve Executive Board.
Lars Søndergaard
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).
Pablo Lamelas
Interventional Cardiologist, Instituto Cardiovascular de Buenos Aires (ICBA)
His areas of interest have centered around Coronary, complex angioplasty, chronic total occlusion angioplasty and structural heart disease interventions.
Won Keun-Kim
Interventional Cardiologist Kerckhoff Heart Center, Bad Nauheim, Germany
Dr Won-Keun Kim is Director of Structural Heart Disease / TAVI at the Kerckhoff Heart Center, Bad Nauheim, Germany. Between 2012-2016 Dr Kim served as Interdisciplinary Consultant, Cardiology / Cardiac Surgery, and Associate Director of the Interventional Cardiology Training Program also at the Kerckhoff Heart Center, where he previously worked as a specialist in cardiology, interventional cardiology and cardiovascular imaging.